Public Notices: Peak Powder River Resources, LLC (F031172/A0016113)
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
08/28/2024 | Press release | Distributed by Public on 08/28/2024 03:53
Please select the service you want to use:
Smartlinks | M&Z plc | Finance | Security Markets | Security Markets | Company News | Securities Issuers | Food Processing Companies | Malta Stock Exchange
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact